IITian still regrets leaving Bengaluru 8 years ago: 'We didn't just leave a city, but ...
startup capital of India
, this founder shared his realization about what the distance from Bengaluru truly cost him: the irreplaceable proximity to innovation, vibrant exchanges of ideas, and a front-row seat to India's growing entrepreneurial wave.
Taking to X, startup founder
Shubham Bansal
wrote how, years ago, driven by frustration over Bengaluru's poor roads and exhausting commute, he and his wife made the decision to relocate from the city to their hometown. On the surface, the move was practical—trading chaos for calm and stress for stability. However, what seemed like a smart escape from urban disorder gradually revealed hidden emotional and professional consequences.
With their departure, they didn't just change geographies. They distanced themselves from their close-knit network of college friends and drifted away from the startup ecosystem's energetic buzz. The constant exchange of groundbreaking ideas, the spontaneous meetups that often sparked new ventures, and the contagious spirit of ambition—all of it was lost. In the process, they also missed out on once-in-a-lifetime professional openings that could have altered the course of their careers.
One of the more profound effects of leaving Bengaluru was how delayed their exposure to emerging technologies became. In the past, they were among the first to dive into new tools, platforms, or innovations. Now, without immediate access to early adopters and trendsetters, they found themselves trailing behind, hearing about revolutionary changes like AI only after they had already disrupted industries. Their identity shifted from pioneers to followers—showing up late to the revolution rather than shaping it from the start.
— BakarBansal (@BakarBansal)
Though life in their hometown was undeniably peaceful and comfortable, something vital always felt missing. It wasn't material—it was an emotional and intellectual longing to stay in touch with the rapidly evolving world of technology and entrepreneurship. A persistent sense of missing out, driven by an innate curiosity and hunger to learn, constantly lingered beneath the surface.
To cope with this gap, Bansal took conscious steps to rebuild his connection to the startup universe. He became an active member of online communities that focused on personal and professional growth, started sharing insights on social platforms like LinkedIn and Twitter, and engaged with people from varied industries to keep learning. He also made it a point to return to Bengaluru every six to eight months. These short but meaningful visits helped him stay attuned to the dynamic landscape of startups, ideas, and innovation that continued to flourish in the city.
Shubham Bansal, an
IIT Bombay
graduate, may have physically stepped away from Bengaluru, but he continues to find ways to keep his spirit tethered to the city that remains at the heart of India's tech evolution.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Nvidia-backed CoreWeave to buy crypto miner Core Scientific in $9 billion deal
Tired of too many ads? Remove Ads Crypto TrackerPowered By TOP COINS TOP COIN SETS XRP 199.63 ( 2.36 %) Buy Solana 13,106.52 ( 0.93 %) Buy BNB 56,732 ( -0.04 %) Buy Ethereum 2,18,472 ( -0.45 %) Buy Bitcoin 92,87,904 ( -0.56 %) Buy Tired of too many ads? Remove Ads Popular in Markets 1. Crypto Gems: Top crypto assets to watch & buy in July 2025 CoreWeave will buy crypto miner Core Scientific in an all-stock deal valued at about $9 billion, the company said on Monday, as AI infrastructure firms race to secure power supply to support their surging acquisition highlights how artificial intelligence companies are moving beyond traditional data centers and looking to repurpose the energy-intensive sites and power contracts bitcoin miners built during the crypto deal will help in the immediate elimination of more than $10 billion of cumulative future lease overhead to be paid for existing contractual sites over the next 12 years, CoreWeave offer represents a $20.40 per share value and implies a premium of nearly 66% to Core Scientific stock's close before reports of potential deal talks first appeared in late Scientific's shares fell 15% before the bell, while Nvidia-backed CoreWeave was last down 4%.The deal is expected to close in the fourth quarter, and the final price will be determined at that time, the companies as an Ethereum-focused crypto miner in 2017, CoreWeave pivoted to AI a few years later. It shuttered its mining business after "The Merge", Ethereum's 2022 upgrade, slashed rewards for revenue has grown at breakneck speed, climbing more than eight-fold last year, according to its IPO deal marks a turnaround for Core Scientific, which filed for bankruptcy in late 2022 following a sharp drop in bitcoin prices and soaring energy costs. The company exited bankruptcy in early Scientific received an unsolicited non-binding proposal from CoreWeave in June last year to acquire all of the company's outstanding the time, Core Scientific had said that the deal significantly undervalued it and was not in the best interests of the company and its two companies signed a series of 12-year contracts then, including an agreement under which Core Scientific would provide CoreWeave with about 200 MW of infrastructure to power its high-performance computing services.
India Today
an hour ago
- India Today
EY CTO calls workforce-wide AI training silly as Microsoft weighs AI in reviews and Google pushes AI playbook
Not everyone is convinced that every employee needs to be trained in AI. While companies like Microsoft are reportedly planning to include AI usage in performance reviews and Google is rolling out an internal AI playbook to guide adoption, EY's Chief Technology Officer for the Americas Consulting division has a very different take. In an interview with Business Insider, the executive said it's 'silly' to expect the entire workforce to upskill in CTO, whose job is to help large organisations integrate AI more meaningfully, believes the real focus should be on designing smarter, easier-to-use systems, not expecting every employee to become an AI expert. 'They just know that they have a screen and an application, they don't need to know how the technology works,' he approach flips the current narrative. Instead of asking workers to change how they function, EY is helping companies build AI tools that work in the background, tools that adjust to existing workflows and roles. One example the CTO shared involved cruise ship staff using AI to predict guest behaviour. Based on weather, guest profiles, and historical data, the AI can forecast movement, product demand, and even suggest shifting staff between venues to manage crowds or increase sales. 'The AI will turn around and list out and build out that process automatically,' he explained. The human in charge then simply approves the plan or makes tweaks using a visual interface. This kind of AI-human collaboration could make AI feel less intimidating and more like an assistant than a is different from what's happening elsewhere. Microsoft is said to be looking at ways to evaluate how well employees are using AI tools as part of their performance metrics, according to internal reports. That naturally puts pressure on employees to pick up AI skills quickly. At the same time, Google has created an internal AI playbook aimed at speeding up AI adoption across teams, though the responsibility still falls on workers to approach shifts that responsibility more onto the technology itself. 'You're not only just giving them technology that's AI-enabled, you're allowing them to start to rethink how they do their job,' the CTO a time when businesses are struggling to balance hype and practical use, this feels like a more grounded strategy. Not everyone needs to know the nuts and bolts of AI — sometimes the best tech just works quietly in the background, helping people do what they already do, only better.- Ends
NDTV
an hour ago
- NDTV
Google Ready To Start Human Trials Of Its AI-Designed Drugs
Google DeepMind's drug discovery company, Isomorphic Labs, is set to launch human trials of its AI-designed drugs. The company is aiming to use cutting-edge AI to design medicines faster, cheaper and more accurately. Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, confirmed to Fortune that the human trials were set to get underway. "There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer. That's happening right now," said Mr Murdoch. "The next big milestone is actually going out to clinical trials, starting to put these things into human beings. We're staffing up now. We're getting very close." Isomorphic Labs was born in the wake of DeepMind's revolutionary AlphaFold AI system that predicts protein structures with high level of accuracy. AlphaFold's creators, Demis Hassabis and John Jumper, both from DeepMind, shared the 2024 Nobel Prize in Chemistry with David Baker from the University of Washington. "This was the inspiration for Isomorphic Lab. It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery," said Mr Murdoch. Isomorphic Labs Since the beginning of Isomorphic Labs in 2021, it has partnered with major pharmaceutical companies like Novartis and Eli Lilly. The company secured $600 million in funding in April 2025 to accelerate the mission. Alongside supporting existing drug programmes, the company is researching and developing new drugs in fields like oncology and immunology. Currently, pharma companies spend millions and years on a single drug development. With only a 10 per cent success rate in trials, Isomorphic Labs is aiming to use AI to boost the odds and reduce the resources required for the entire process. "We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical haven't got that yet, but we're making good progress," said Mr Murdoch. "We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful. One day we hope to be able to say, well, here's a disease, and then click a button and out pops the design for a drug to address that disease. All powered by these amazing AI tools," he added.
